Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer.

Bari, Shahla; Muzaffar, Jameel; Chan, Austin; Jain, Sanjay R; Haider, Ahmad M; Adams Curry, Marjorie; Hostler, Christopher J

Bari, Shahla; Muzaffar, Jameel; Chan, Austin; Jain, Sanjay R; Haider, Ahmad M; Adams Curry, Marjorie; Hostler, Christopher J.

Afiliação

Bari S; Internal Medicine, Morehouse School of Medicine, Atlanta, GA, USA.
Muzaffar J; Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Chan A; Morehouse School of Medicine, Atlanta, GA, USA.
Jain SR; Morehouse School of Medicine, Atlanta, GA, USA.
Haider AM; AGCO Corporation, Atlanta, Georgia, USA.
Adams Curry M; Grady Health System, Department of Pharmacy and Drug Information, Atlanta, USA.
Hostler CJ; Division of Infectious Diseases, Duke University Health System, Durham VA Health Care System, Durham, NC, USA.

J Oncol ; 2019: 2989048, 2019.

Article em En | MEDLINE | ID: mdl-31275380

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article